Hermine I. Brunner
About
Hermine I. Brunner is a scholar working on Rheumatology, Hematology and Immunology.
According to data from OpenAlex, Hermine I. Brunner has authored 240 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 145 papers in Rheumatology, 130 papers in Hematology and 64 papers in Immunology. Recurrent topics in Hermine I. Brunner's work include Autoimmune and Inflammatory Disorders Research (128 papers), Systemic Lupus Erythematosus Research (117 papers) and Adolescent and Pediatric Healthcare (62 papers). Hermine I. Brunner is often cited by papers focused on Autoimmune and Inflammatory Disorders Research (128 papers), Systemic Lupus Erythematosus Research (117 papers) and Adolescent and Pediatric Healthcare (62 papers). Hermine I. Brunner collaborates with scholars based in United States, Italy and Canada. Hermine I. Brunner's co-authors include Rina Mina, Earl D. Silverman, Brian M. Feldman, Daniel J. Lovell, Marisa S. Klein‐Gitelman, Murray H. Passo, Edward H. Giannini, Claire Bombardier, Prasad Devarajan and Nicolino Ruperto and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Journal of Immunology and Kidney International.
In The Last Decade
Hermine I. Brunner
223 papers receiving 7.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Hermine I. Brunner United States | 48 | 4.2k | 2.5k | 2.4k | 1.2k | 1.1k | 240 | 7.4k | ||
| Earl D. Silverman Canada | 61 | 6.5k 1.6× | 3.5k 1.4× | 3.3k 1.4× | 1.0k 0.9× | 951 0.9× | 258 | 12.1k | ||
| Michael W. Beresford United Kingdom | 40 | 2.1k 0.5× | 1.5k 0.6× | 1.3k 0.5× | 643 0.5× | 540 0.5× | 161 | 4.9k | ||
| Graciela S. Alarcón United States | 57 | 8.8k 2.1× | 1.5k 0.6× | 3.9k 1.6× | 926 0.8× | 126 0.1× | 320 | 12.5k | ||
| Lori B. Tucker Canada | 36 | 1.7k 0.4× | 1.1k 0.5× | 830 0.3× | 386 0.3× | 736 0.7× | 127 | 3.7k | ||
| A. Zink Germany | 51 | 7.7k 1.8× | 3.3k 1.3× | 3.1k 1.3× | 109 0.1× | 403 0.4× | 238 | 11.3k | ||
| Kimme L Hyrich United Kingdom | 63 | 7.6k 1.8× | 3.8k 1.5× | 3.2k 1.3× | 85 0.1× | 792 0.7× | 313 | 12.2k | ||
| Özgür Kasapçopur Türkiye | 36 | 958 0.2× | 1.3k 0.5× | 1.3k 0.6× | 636 0.5× | 356 0.3× | 325 | 4.5k | ||
| David D’Cruz United Kingdom | 52 | 6.5k 1.5× | 1.1k 0.4× | 4.0k 1.7× | 1.1k 0.9× | 70 0.1× | 279 | 10.8k | ||
| Caroline Gordon United Kingdom | 67 | 12.5k 3.0× | 1.4k 0.6× | 8.0k 3.3× | 1.3k 1.1× | 158 0.1× | 305 | 17.3k | ||
| Pilar Brito‐Zerón Spain | 47 | 3.3k 0.8× | 1.1k 0.4× | 1.9k 0.8× | 334 0.3× | 88 0.1× | 120 | 8.8k |
Countries citing papers authored by Hermine I. Brunner
Since
Specialization
Citations
This map shows the geographic impact of Hermine I. Brunner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hermine I. Brunner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hermine I. Brunner more than expected).
Fields of papers citing papers by Hermine I. Brunner
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Hermine I. Brunner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hermine I. Brunner. The network helps show where Hermine I. Brunner may publish in the future.
Co-authorship network of co-authors of Hermine I. Brunner
This figure shows the co-authorship network connecting the top 25 collaborators of Hermine I. Brunner. A scholar is included among the top collaborators of Hermine I. Brunner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hermine I. Brunner. Hermine I. Brunner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Zhao, Junfang, Xueheng Zhao, Tomoyuki Mizuno, et al.. (2025). Volumetric Absorptive Microsampling Combined with Mass Spectrometry to Support Pharmacokinetically-Guided Precision Dosing of Mycophenolate Mofetil in Pediatric Lupus Nephritis Patients. The Journal of Applied Laboratory Medicine. 10(4). 806–819.
2.
Singer, Nora G., Jennifer Huggins, Kalyani Marathe, et al.. (2025). Pharmacokinetics, effectiveness, tolerability and effect on quality of life of open-label tofacitinib for the treatment of moderately active mucocutaneous manifestations of SLE: results of a 76-week phase II study. Lupus Science & Medicine. 12(2). e001689–e001689.
3.
Maccora, Ilaria, Hermine I. Brunner, Amy Cassedy, et al.. (2024). Achieving Medication‐Free Remission in Patients With Juvenile Dermatomyositis. ACR Open Rheumatology. 7(1). e11751–e11751.
4.
Eberhard, B. Anne, Jennifer Huggins, Marisa S. Klein‐Gitelman, et al.. (2024). Implementation of the Lupus Low Disease Activity State in Pediatric Rheumatology Care: The Role of the Visual Analog Scale. ACR Open Rheumatology. 7(1). e11737–e11737.
5.
Brunner, Hermine I., Esraa M. Eloseily, Yonatan Butbul Aviel, et al.. (2024). Biomarker Changes in Response to Tofacitinib Treatment in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis. Arthritis Care & Research. 76(12). 1723–1732.
6.
Brunner, Hermine I., Anna Shmagel, Gerd Horneff, et al.. (2024). Pharmacokinetics, Efficacy, and Safety of Upadacitinib in Pediatric Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open‐Label, Phase 1 Trial. Arthritis Care & Research. 77(5). 584–593.
7.
Brunner, Hermine I., Nikolay Tzaribachev, Ingrid Louw, et al.. (2023). Long‐Term Maintenance of Clinical Responses by Individual Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis Treated With Abatacept. Arthritis Care & Research. 75(11). 2259–2266.
8.
Brunner, Hermine I., Aisha Vadhariya, Christina Dickson, et al.. (2023). Treatment patterns in paediatric and adult patients with SLE: a retrospective claims database study in the USA. Lupus Science & Medicine. 10(2). e000817–e000817.
9.
Gerß, Joachim, Ariane Klein, Gerd Horneff, et al.. (2022). Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial. Annals of the Rheumatic Diseases. 81(7). 990–997.
10.
Ruperto, Nicolino, Hermine I. Brunner, Nikolay Tzaribachev, et al.. (2021). Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis. The Journal of Rheumatology. 48(7). 1073–1081.
11.
Brunner, Hermine I., Carlos Abud‐Mendoza, Masaaki Mori, et al.. (2021). Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. RMD Open. 7(3). e001747–e001747.
12.
Lovell, Daniel J., Bin Huang, Chen Chen, et al.. (2021). Prevalence of autoimmune diseases and other associated conditions in children and young adults with juvenile idiopathic arthritis. RMD Open. 7(1). e001435–e001435.
13.
Quartier, Pierre, Е.I. Alexeeva, Tamás Constantin, et al.. (2020). Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open‐Label, Randomized Study. Arthritis & Rheumatology. 73(2). 336–346.
14.
Huang, Bin, Tingting Qiu, Chen Chen, et al.. (2020). Timing matters: real-world effectiveness of early combination of biologic and conventional synthetic disease-modifying antirheumatic drugs for treating newly diagnosed polyarticular course juvenile idiopathic arthritis. RMD Open. 6(1). e001091–e001091.
15.
Smitherman, Emily A., et al.. (2019). Quality of Care in Childhood-onset Systemic Lupus Erythematosus: Report of an Intervention to Improve Cardiovascular and Bone Health Screening. The Journal of Rheumatology. 47(10). 1506–1513.
16.
Jones, Jordan T., Adam C. Carle, Jiha Lee, et al.. (2016). Validation of Patient‐Reported Outcomes Measurement Information System Short Forms for Use in Childhood‐Onset Systemic Lupus Erythematosus. Arthritis Care & Research. 69(1). 133–142.
17.
Malattia, Clara, Nicolino Ruperto, Elena Palmisani, et al.. (2013). Assessment of Radiographic Progression in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Results From the TENDER Trial. UCL Discovery (University College London). 65.
18.
Sherwin, Catherine M.T., et al.. (2011). Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood‐onset systemic lupus erythematosus. British Journal of Clinical Pharmacology. 73(5). 727–740.
19.
Brunner, Hermine I., Earl D. Silverman, Claire Bombardier, & Brian M. Feldman. (2003). European Consensus Lupus Activity Measurement is sensitive to change in disease activity in childhood‐onset systemic lupus erythematosus. Arthritis Care & Research. 49(3). 335–341.
20.
Brunner, Hermine I., S. Ballinger, Suzanne L. Bowyer, et al.. (2001). Current Medication Choices in Juvenile Rheumatoid Arthritis II –Update of a Survey Performed in 1993. JCR Journal of Clinical Rheumatology. 7(5). 295–300.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Earl D. Silverman Breakdown of academic impact, for papers by Michael W. Beresford Breakdown of academic impact, for papers by Graciela S. Alarcón Breakdown of academic impact, for papers by Lori B. Tucker Breakdown of academic impact, for papers by A. Zink Breakdown of academic impact, for papers by Kimme L Hyrich Breakdown of academic impact, for papers by Özgür Kasapçopur Breakdown of academic impact, for papers by David D’Cruz Breakdown of academic impact, for papers by Caroline Gordon Breakdown of academic impact, for papers by Pilar Brito‐Zerón